Posted by Michael Wonder on 25 Jun 2022

Novartis receives positive CHMP opinion for Scemblix, a novel treatment for adult patients with chronic myeloid leukaemia

24 June 2022 - 

Read Novartis press release

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Europe